Yorkshire Terrier Gut Health: When Their Gut Loses Protein

Summary

Yorkshire Terrier gut health is defined by conditions that are genuinely breed-specific, often slow in onset, and frequently misattributed to a general “sensitive stomach.” The most clinically serious of these is Yorkshire Terrier Enteropathy (YTE), a form of chronic inflammatory enteropathy with a particularly strong association with intestinal lymphangiectasia and protein-losing enteropathy (PLE). In lymphangiectasia, the lymphatic vessels within the small intestinal mucosa become dilated and dysfunctional, allowing protein-rich lymph to leak into the gut lumen and be lost in the faeces. The result, in progressive cases, is hypoalbuminaemia, fluid accumulation, and significant deterioration in condition. Research has confirmed that Yorkshire Terriers are consistently over-represented in PLE studies and carry distinct patterns of gut dysbiosis that persist even after clinical remission. A secondary layer of hepatic vulnerability, through portosystemic shunts and hepatic microvascular dysplasia, gives this breed a meaningful gut-liver axis dimension alongside the primary gut-immune lead. Targeted microbiome support is the most practical daily intervention available to owners.

---

Introduction

The Yorkshire Terrier is one of the most popular small breeds in the United Kingdom, beloved for its confidence, character, and companionship. What is less widely appreciated is that this breed carries a disproportionate burden of gastrointestinal disease relative to its small body size, including a group of conditions that can develop slowly, present subtly in their early stages, and produce serious clinical consequences if left unmanaged.

At the centre of this picture is Yorkshire Terrier Enteropathy (YTE), a breed-specific form of chronic inflammatory enteropathy distinguished by its strong association with intestinal lymphangiectasia and protein-losing enteropathy. This is not the general digestive sensitivity that affects many dogs intermittently. In the Yorkshire Terrier, the gut-immune architecture is constitutionally more vulnerable than in most other breeds, and the consequences of mucosal breakdown can include the loss of protein directly through the gut wall, producing a slow and often invisible deterioration in condition that owners frequently mistake for ageing or general picky eating.

A secondary dimension of Yorkshire Terrier gut health involves the liver. This breed has a documented predisposition to portosystemic shunts and hepatic microvascular dysplasia, conditions that create a meaningful gut-liver axis narrative. A dysbiotic gut microbiome increases the burden of microbial metabolites and endotoxins reaching the liver via the portal system. In a breed where hepatic function is already under constitutional pressure, maintaining gut barrier integrity and a healthy microbiome is directly relevant to liver health as well as gut health. Understanding these two axes together gives a more complete picture of why gut support matters so much in this breed.

Key Takeaways

• Yorkshire Terriers are consistently over-represented in studies of intestinal lymphangiectasia and protein-losing enteropathy, and are considered one of the highest-risk breeds for these conditions.
• The protein loss in lymphangiectasia occurs when dilated gut lymphatics leak protein-rich fluid into the intestinal lumen, leading to hypoalbuminaemia, oedema, and in severe cases ascites and pleural effusion.
• Yorkshire Terrier Enteropathy (YTE) is a recognised breed-specific form of chronic inflammatory enteropathy with distinct histopathological features, including villous stunting, crypt lesions, and variable inflammatory infiltration.
• Research has confirmed measurable gut dysbiosis in Yorkshire Terriers with YTE, with specific reductions in beneficial taxa such as Fusobacterium and Clostridium hiranonis, and disruptions to bile acid and fatty acid metabolism.
• A secondary gut-liver axis is clinically relevant in this breed because of a documented predisposition to portosystemic shunts and hepatic microvascular dysplasia, conditions that increase the liver’s vulnerability to gut-derived inflammatory burden.
• Dysbiosis in Yorkshire Terriers with YTE does not reliably normalise with clinical remission alone, indicating the need for ongoing microbiome support beyond symptom resolution.
• Dietary management, including fat restriction and consistency, is an important component of YTE management alongside any veterinary treatment.

In This Guide:

• The Gut Health Profile of the Yorkshire Terrier
• Yorkshire Terrier Enteropathy: A Breed-Specific Gut Condition
• Intestinal Lymphangiectasia and Protein-Losing Enteropathy in Yorkshire Terriers
• The Gut-Immune Axis: Mucosal Immunity and Chronic Enteropathy in Yorkshire Terriers
• Hepatic Vulnerability and the Gut-Liver Axis in Yorkshire Terriers
• Yorkshire Terrier Gut Dysbiosis: What the Research Shows
• How Bonza Supports Yorkshire Terrier Gut Health
• How To Support Your Yorkshire Terrier’s Gut Health: A Practical Guide
• Safety Considerations and When to See Your Vet
• Frequently Asked Questions
• Conclusion
• Related Articles
• References
• Editorial Information

---

The Gut Health Profile of the Yorkshire Terrier

Yorkshire Terrier gut health problems are not incidental or random. They arise from a mucosal immune and lymphatic architecture that is constitutionally more vulnerable in this breed than in most others, and they cluster around three converging drivers that reinforce one another when the gut environment deteriorates.

The primary driver is intestinal lymphangiectasia and the protein-losing enteropathy it produces. This is the most clinically serious gut condition the breed faces, and the one most likely to be missed or underestimated in its early stages. The second driver is the broader spectrum of Yorkshire Terrier Enteropathy, encompassing food-responsive and immune-mediated inflammatory enteropathies that share the same mucosal immune platform. The third is hepatic vulnerability: a documented predisposition to portosystemic shunts and hepatic microvascular dysplasia that makes gut-derived microbial burden a more consequential issue in this breed than in others.

What unifies all three drivers is the gut microbiome. Microbial diversity and composition influence mucosal barrier integrity, modulate the intestinal immune environment that governs lymphangiectasia progression, and determine the composition and volume of bacterial metabolites and translocation products that the liver must process. In the Yorkshire Terrier, supporting the microbiome is not a general wellness aspiration: it is a primary health management requirement with genuine clinical relevance.

---

Yorkshire Terrier Enteropathy: A Breed-Specific Gut Condition

Yorkshire Terrier Enteropathy (YTE) is a recognised form of chronic inflammatory enteropathy (CIE) that presents differently in this breed than in the broader canine population, and that has been characterised in dedicated breed-specific research.¹ Retrospective studies of Yorkshire Terriers with protein-losing enteropathy have consistently identified clinical and histopathological patterns that set this breed apart: crypt lesions of a type uncommon in other breeds, a strong association with lymphangiectasia, and a pattern of hypoalbuminaemia accompanied by electrolyte disturbances, including hypocalcaemia and hypomagnesaemia, that reflect the systemic consequences of intestinal protein and nutrient loss.⁹

The spectrum of YTE includes food-responsive enteropathy, immune-mediated enteropathy, and the lymphangiectasia-associated protein-losing presentation that is most clinically distinctive in this breed. In food-responsive cases, the mucosal immune response to dietary antigens drives chronic intestinal inflammation; in immune-mediated presentations, the inflammation is self-sustaining and requires immunosuppressive management. In practice, the two often overlap, and the lymphangiectasia that develops in many affected Yorkshire Terriers may represent a downstream consequence of mucosal inflammation rather than a purely structural anomaly.

Females are over-represented in reported Yorkshire Terrier PLE cohorts, and median age at presentation has been reported at around seven years, with a range from one to twelve.¹ This broad age range matters clinically because it underlines that YTE can develop in relatively young dogs and that the absence of dramatic symptoms in a young Yorkshire Terrier does not mean the gut is healthy.

What makes YTE particularly important from an owner perspective is its tendency to present subtly. Intermittent soft stools, mild weight loss, occasional vomiting, or unexplained lethargy may precede the more obvious signs of hypoalbuminaemia by months or years. By the time ascites or respiratory difficulty appear, the condition has often been progressing for some time. Early recognition and proactive gut support are therefore far more valuable than waiting for overt clinical signs.²

---

Intestinal Lymphangiectasia and Protein-Losing Enteropathy in Yorkshire Terriers

To understand the most distinctive and serious aspect of Yorkshire Terrier gut health, it is necessary to understand what intestinal lymphangiectasia actually does inside the gut wall, and why the Yorkshire Terrier is so vulnerable to it.

The small intestinal mucosa contains a network of lymphatic capillaries called lacteals, which run through each villus and drain into the submucosal and mesenteric lymphatic system. Under normal conditions, these lacteals absorb dietary fats processed into chylomicrons after digestion, along with fat-soluble vitamins and a proportion of the proteins and cells circulating in the lymph. They carry this lymph upward through the lymphatic vasculature into the thoracic duct and ultimately into the systemic circulation.

In intestinal lymphangiectasia, this drainage pathway fails. The lacteals and the broader intestinal lymphatic vessels dilate, and lymphatic pressure builds within the mucosal architecture. Under this elevated pressure, the walls of the lacteals rupture or become sufficiently permeable that protein-rich lymph leaks not upward into the circulation where it belongs, but downward and outward into the intestinal lumen.² The gut, in this condition, is doing the opposite of what it is supposed to do: instead of absorbing protein from the lumen into the body, it is losing protein from the body into the lumen, where it is excreted in the faeces.

The consequences of this sustained protein loss are systemic and cumulative. Albumin, the principal plasma protein responsible for maintaining oncotic pressure in the bloodstream, falls progressively. As oncotic pressure drops, fluid that would normally remain within blood vessels begins to accumulate in body cavities: the abdomen, the chest, and the limbs. Hypoalbuminaemia drives ascites, pleural effusion, and peripheral oedema. Secondary disturbances develop in calcium and magnesium, because these minerals are partly transported in protein-bound form and their intestinal absorption is disrupted by the same mucosal dysfunction.⁹ In advanced cases, hypocalcaemia produces muscle tremors or seizures. Total cholesterol falls, because lymph carries chylomicrons from the gut, and when that lymph is lost from the system, serum cholesterol declines alongside it.¹

Yorkshire Terriers are consistently over-represented in studies of intestinal lymphangiectasia across the canine population.¹² ³ The reason for this predisposition is not fully understood, but breed predisposition of this consistency implies a heritable component, whether in the structure of the intestinal lymphatic architecture itself, in the mucosal immune environment that governs inflammation-driven lymphatic obstruction, or in both. What the research confirms is that this breed’s risk is real, sustained across multiple independent study populations, and not simply an artefact of ascertainment bias.

A retrospective study of thirty Yorkshire Terriers with PLE found that common presenting signs included diarrhoea, vomiting, ascites with abdominal distension, and respiratory difficulty.¹ Of the twenty-three dogs for which long-term follow-up was available, nine achieved complete resolution of clinical signs, three achieved partial resolution, and eleven failed to respond to treatment. Four dogs died acutely. Median survival in responders was forty-four months; in non-responders, twelve months. Variables predictive of poor outcome included vomiting at presentation, severity of hypoalbuminaemia, and the degree of villous stunting on histopathology.¹ These are not statistics to alarm owners, but they do underscore why early identification and proactive management matter so much in this breed.

A separate retrospective study in French private practice, examining thirty-one Yorkshire Terriers with PLE, found that ascites without any gastrointestinal signs was the sole presenting finding in over forty per cent of cases.¹⁰ This is a critical clinical observation. It means that a significant proportion of affected Yorkshire Terriers present with fluid accumulation rather than digestive symptoms, and that the gut is the source of the problem even when the gut appears, on the surface, to be behaving normally. Owners and veterinarians looking only for diarrhoea may miss the diagnosis in these dogs entirely.

---

The Gut-Immune Axis: Mucosal Immunity and Chronic Enteropathy in Yorkshire Terriers

The gut-immune axis describes the bidirectional relationship between the gut microbiome, the mucosal immune system, and systemic immune function. In the Yorkshire Terrier, this axis is the primary lens through which YTE and lymphangiectasia should be understood. For a deeper exploration of how this axis operates across all breeds, our Gut-Immune Axis pillar article provides comprehensive coverage. This section focuses on what is specific and clinically important in the Yorkshire Terrier.

The intestinal mucosa is the site of continuous negotiation between the immune system and the gut microbiome. Under healthy conditions, the gut-associated lymphoid tissue (GALT) maintains a state of controlled tolerance: recognising commensal bacteria as safe, mounting appropriate responses to genuine pathogens, and preventing the chronic activation of inflammatory cascades against food antigens or normal gut inhabitants. This balance depends on the integrity of the mucosal barrier, the composition of the microbiome, and the regulatory capacity of the mucosal immune system.

In Yorkshire Terriers with YTE, this balance is disrupted. The mucosal immune response is dysregulated in a way that is breed-specific, producing the chronic inflammatory infiltration and lymphatic architectural damage that characterise the condition histologically. Whether this dysregulation precedes the lymphangiectasia or arises as a consequence of it is not fully established.² What is clear is that the two processes are intertwined: mucosal inflammation drives lymphatic obstruction, and lymphatic dysfunction amplifies the mucosal immune environment in which further inflammation develops.

Chronic inflammatory enteropathy in dogs, including YTE, is consistently associated with measurable shifts in the gut microbiome, with alterations in mucosal immune regulation, and with disruption of the metabolic functions that beneficial bacteria perform.⁷ These shifts include reductions in bacteria that produce short-chain fatty acids supportive of mucosal barrier integrity, depletion of taxa with bile acid-processing roles, and expansion of potential pathobionts. The relationship is bidirectional: dysbiosis worsens mucosal inflammation, and mucosal inflammation worsens dysbiosis.⁶

For Yorkshire Terrier owners, the practical implication is that supporting the microbiome is not merely about digestive comfort. It is about maintaining the microbial environment in which mucosal immune regulation can function appropriately, and in which the structural integrity of the gut wall is actively supported by the short-chain fatty acids and other metabolites that beneficial bacteria produce. A microbiome in poor condition is a predisposing factor for the kind of mucosal immune breakdown that YTE represents.

---

Hepatic Vulnerability and the Gut-Liver Axis in Yorkshire Terriers

The gut-liver axis is the second major axis of clinical relevance in Yorkshire Terrier gut health, and it adds an important layer to why gut support matters in this breed beyond the digestive system alone. Our Gut-Liver Axis pillar article covers the underlying mechanisms in depth. Here we focus on what is breed-specific.

Yorkshire Terriers have a documented predisposition to two hepatic conditions that place the liver under constitutional strain: extrahepatic portosystemic shunts and hepatic microvascular dysplasia (HMD). Extrahepatic portosystemic shunts are among the most common congenital hepatic vascular anomalies in small and toy breed dogs, with Yorkshire Terriers consistently identified as one of the highest-risk breeds.¹⁰ HMD, a microscopic intrahepatic circulatory disorder involving maldevelopment of tertiary portal vein branches, is particularly well characterised in Cairn Terriers and Yorkshire Terriers, and may occur concurrently with a gross portosystemic shunt or as an isolated finding.¹⁰

In dogs with portosystemic shunts or HMD, venous blood from the gastrointestinal tract bypasses normal hepatic filtration. The liver, which normally receives portal blood and removes ammonia, bacterial products, endotoxins, and other absorbed substances before they reach the systemic circulation, is partially or substantially circumvented. The consequences include hepatic encephalopathy, growth abnormalities, urinary tract complications, and a generalisable reduction in the liver’s functional reserve.

This creates a meaningful gut-liver axis dimension specific to the Yorkshire Terrier. Even in dogs without overt portosystemic shunting, gut dysbiosis and a compromised mucosal barrier increase the volume of lipopolysaccharide, bacterial translocation products, and other microbially derived molecules that reach the portal circulation and must be processed by the liver.⁸ In most breeds, the liver handles this background burden with relative ease. In a Yorkshire Terrier whose hepatic architecture is constitutionally less efficient, the same dysbiotic load represents a proportionally greater challenge to liver health.

Research in dogs with chronic hepatobiliary disease has confirmed that the gut microbiome is measurably altered compared to healthy controls, with reductions in taxa including Clostridium hiranonis, a bile acid-metabolising bacterium important to both gut and hepatic health.⁸ The direction of causality between hepatic disease and dysbiosis is bidirectional: liver dysfunction impairs bile secretion and antimicrobial defences in the gut, worsening dysbiosis; and dysbiosis increases the translocation burden on the liver, worsening hepatic inflammation.⁸

For Yorkshire Terrier owners, this gut-liver dimension is a further argument for treating microbiome support as a daily priority rather than a reactive intervention. Maintaining a healthy gut barrier and a diverse, functional microbiome reduces the gut-derived inflammatory input to the liver, which matters in a breed where hepatic reserve may be reduced even in the absence of a diagnosed shunt.

---

Yorkshire Terrier Gut Dysbiosis: What the Research Shows

Research specifically into the gut microbiome of Yorkshire Terriers with YTE has produced findings that are both clinically informative and practically important for owners and practitioners.

A prospective study of Yorkshire Terriers with active YTE, dogs in clinical remission, and healthy Yorkshire Terrier controls confirmed a high incidence of gut dysbiosis in the disease group.⁴ Using the validated Dysbiosis Index, which quantifies shifts in seven key bacterial taxa as a single numeric value, the study found that dogs with active YTE had significantly elevated dysbiosis scores compared to healthy controls. Dysbiosis severity correlated with clinical severity. Of particular importance was the finding that the abundance of Fusobacterium and Clostridium hiranonis was significantly reduced in YTE dogs compared to healthy controls.⁴ Clostridium hiranonis plays a critical role in the conversion of primary to secondary bile acids within the gut, and its depletion has been linked to disrupted bile acid metabolism and amplified intestinal inflammation in chronic enteropathies.⁶

The study also identified significant perturbations in fecal fatty acid and sterol profiles in Yorkshire Terriers with YTE, reflecting disrupted lipid absorption and metabolism consistent with the mucosal dysfunction and lymphatic compromise that characterise this breed’s PLE presentation.⁴

A subsequent microbiome analysis examining bacterial composition across YTE dogs during disease and remission, and comparing both groups to healthy Yorkshire Terrier controls, produced a finding with direct practical significance.⁵ Significant differences in microbiome composition existed between YTE dogs and healthy controls. However, no significant difference was found between dogs in clinical remission and those with active disease in terms of overall microbiome recovery.⁵ In other words, clinical improvement did not predict microbiome normalisation. The gut dysbiosis associated with YTE persisted beyond the resolution of clinical signs, suggesting that the microbiome remains disturbed even when the dog appears well.

This finding is clinically important for several reasons. It means that a Yorkshire Terrier that has responded to treatment and appears to be in remission may still be carrying a significantly altered gut microbiome. That altered microbiome represents a biological risk factor for relapse and ongoing mucosal vulnerability. It argues strongly for the continuation of microbiome support as a long-term strategy rather than a short-term intervention tied to the period of overt illness.⁵

For a broader understanding of how dysbiosis develops and can be addressed across all dogs, our Gut Dysbiosis article provides detailed coverage.

---

How Bonza Supports Yorkshire Terrier Gut Health

Three Bonza products carry specific relevance for Yorkshire Terriers, each targeting a different dimension of this breed’s gut health profile. The product bridge in this breed is not about stacking supplements but about identifying the right daily foundation and the most appropriate secondary support based on each individual dog’s presentation.

Biotics: The Daily Non-Negotiable

Biotics is the most important daily supplement for Yorkshire Terrier owners and the non-negotiable foundation for this breed. Its relevance is direct: Yorkshire Terriers face constitutionally elevated risk of mucosal immune dysregulation, intestinal lymphangiectasia, and gut dysbiosis that may persist even during clinical remission. Each of these risk factors is influenced by the composition, diversity, and functional health of the gut microbiome.

Biotics delivers the full Biotics Triad: prebiotics in the form of MOS and FOS, which nourish and selectively support beneficial bacterial communities; Calsporin® (Bacillus velezensis DSM 15544), the sole live probiotic, which contributes to mucosal barrier integrity and gut-immune modulation; and TruPet™ postbiotic and the heat-inactivated postbiotic, Lactobacillus helveticus HA-122, which provide a stable, cell-wall-derived signal that may help support gut-associated immune regulation. Together, these three components support the microbial environment in which mucosal immunity can function appropriately, the barrier through which protein loss begins when compromised, and the metabolic conditions in which secondary bile acid production and other beneficial microbial functions can occur.

For a Yorkshire Terrier whose microbiome research shows persistent dysbiosis even in remission, daily prebiotic, probiotic, and postbiotic support is the most practical intervention available to owners who want to reduce ongoing gut vulnerability and support the conditions for long-term mucosal health.

Belly: Primary Secondary Recommendation

Belly is the primary secondary recommendation for Yorkshire Terriers with a history of soft stools, loose faeces, digestive irregularity, or any presentation consistent with food-responsive enteropathy or broader gut sensitivity. Belly’s formulation addresses gut motility and mucosal lining support, making it the most directly relevant supplementary option for the full enteropathy picture in this breed beyond the microbiome foundation.

Yorkshire Terriers with YTE and those with food-responsive digestive sensitivity share a common underlying vulnerability in the mucosal architecture of the small intestine. Belly is appropriate where the clinical picture is predominantly gut-focused and where the owner’s primary concern is managing digestive symptoms and supporting the mucosal environment in which those symptoms arise.

Block: Alternative for the Gut-Skin-Immune Presentation

Block is relevant for the subset of Yorkshire Terriers whose presentation includes immune-reactive skin signs alongside gut symptoms. The gut-skin-immune intersection is well established, and some Yorkshire Terriers present with a combined picture in which skin reactivity and gut dysregulation occur together, reflecting a shared mucosal immune vulnerability across organ systems.

Block is positioned as an alternative secondary recommendation to Belly for this subgroup, not as a supplement to be used alongside Belly. Where the clinical picture includes both gut sensitivity and skin immune reactivity, Block may be the more appropriate choice. Where the presentation is primarily gastrointestinal, Belly remains the first recommendation.

For a full explanation of the three-layer prebiotic, probiotic and postbiotic framework that underpins these recommendations, see Gut Health Supplements for Dogs: Why Probiotics Alone Are Not Enough.

---

How To Support Your Yorkshire Terrier’s Gut Health: A Practical Guide

---

Safety Considerations and When to See Your Vet

Biotics, Belly, and Block are supplementary products designed to support the gut microbiome and mucosal health, not to diagnose, treat, or replace veterinary management of clinical disease. This distinction matters particularly in Yorkshire Terriers because of the seriousness of the conditions this breed is predisposed to.

Any Yorkshire Terrier showing the following signs warrants prompt veterinary assessment: abdominal distension or bloating, rapid unexplained weight loss, persistent vomiting or diarrhoea, respiratory difficulty, lethargy that is new or worsening, or visible swelling of the limbs. These are potential indicators of hypoalbuminaemia, fluid accumulation, or systemic consequences of protein-losing enteropathy, all of which require clinical investigation and management.

A diagnosis of PLE, YTE, or lymphangiectasia is made through a combination of clinical examination, blood biochemistry, abdominal ultrasound, and intestinal histopathology. These are veterinary investigations that cannot be replaced by supplementation or dietary change alone. If a diagnosis has been made and immunosuppressive or anti-inflammatory medications have been prescribed, dietary management and microbiome support may be appropriate adjuncts, but should be discussed with your veterinarian before introduction.

For Yorkshire Terriers with suspected or confirmed portosystemic shunts or hepatic microvascular dysplasia, the gut-liver axis considerations described in this article make gut support additionally relevant, but again within a veterinary management framework appropriate to each individual dog’s condition.

---

Frequently Asked Questions

---

Conclusion

The Yorkshire Terrier’s gut health profile is one of the most clinically compelling in small breed gastroenterology, not because these are fragile dogs in a general sense, but because the conditions they are predisposed to, including intestinal lymphangiectasia, YTE, and the associated protein-losing enteropathy, represent a genuinely serious risk when they are not identified early and managed proactively.

The research picture is clear. Yorkshire Terriers are over-represented in PLE studies, carry a distinct pattern of gut dysbiosis with specific microbial features, and show persistent microbiome disruption even after clinical signs resolve. The liver adds a second axis of vulnerability that elevates the case for gut support beyond the digestive system into hepatic health. Together, these factors make consistent, long-term microbiome support not a comfort intervention but a practical and evidence-informed strategy for a breed that genuinely needs it.

The message for owners is one of proactive awareness rather than alarm. A Yorkshire Terrier that is eating well and appears comfortable may still be developing the slow, subclinical changes that precede overt PLE. Regular veterinary monitoring, dietary consistency, and daily microbiome support through the full Biotics Triad are the most practical tools available for maintaining the gut environment in which these risks are minimised. Understanding what is happening inside the gut wall of this breed, and acting on that understanding consistently, is what makes the difference between early intervention and a crisis.

---

Related Articles

• The Dog Gut Microbiome: Vital Key to Dog Health
• The Gut-Immune Axis in Dogs: How Gut Health Supports Immune Health
• The Gut-Liver Axis in Dogs: Supporting Vital Detoxification
• Best Probiotics for Dogs: Canine Nutritionist’s Guide to Real Gut Impact
• Best Prebiotics for Dogs: Canine Nutritionist’s Complete Guide
• Gut Health Supplements for Dogs: Why Probiotics Alone Are Not Enough
• Gut Dysbiosis in Dogs: Causes, Symptoms & How to Restore Balance

---

References

1. Simmerson SM, Armstrong PJ, Wünschmann A, Jessen CR, Crews LJ, Washabau RJ. Clinical features, intestinal histopathology, and outcome in protein-losing enteropathy in Yorkshire Terrier dogs. J Vet Intern Med. 2014;28(2):331-337. doi: 10.1111/jvim.12291. PMID: 24467282. PMC: PMC4857982.
2. Craven MD, Washabau RJ. Comparative pathophysiology and management of protein-losing enteropathy. J Vet Intern Med. 2019;33(2):383-402. doi: 10.1111/jvim.15406. PMID: 30762910. PMC: PMC6430879.
3. Jablonski SA. Pathophysiology, diagnosis, and management of canine intestinal lymphangiectasia: a comparative review. Animals (Basel). 2022;12(20):2791. doi: 10.3390/ani12202791. PMID: 36290177. PMC: PMC9597800.
4. Galler AI, Suchodolski JS, Steiner JM, Sung CH, Hittmair KM, Richter B, Burgener IA. Microbial dysbiosis and fecal metabolomic perturbations in Yorkshire Terriers with chronic enteropathy. Sci Rep. 2022;12(1):12977. doi: 10.1038/s41598-022-17244-6. PMID: 35902689. PMC: PMC9334271.
5. Doulidis PG, Galler AI, Hausmann B, Berry D, Rodríguez-Rojas A, Burgener IA. Gut microbiome signatures of Yorkshire Terrier enteropathy during disease and remission. Sci Rep. 2023;13(1):4337. doi: 10.1038/s41598-023-31024-w. PMID: 36927871. PMC: PMC10018597.
6. Pilla R, Suchodolski JS. The role of the canine gut microbiome and metabolome in health and gastrointestinal disease. Front Vet Sci. 2020;6:498. doi: 10.3389/fvets.2019.00498. PMID: 31993446. PMC: PMC6971114.
7. Jergens AE, Heilmann RM. Canine chronic enteropathy: current state-of-the-art and emerging concepts. Front Vet Sci. 2022;9:923013. doi: 10.3389/fvets.2022.923013. PMID: 36213409. PMC: PMC9534534.
8. Habermaass V, Olivero D, Gori E, Mariti C, Longhi E, Marchetti V. Intestinal microbiome in dogs with chronic hepatobiliary disease: can we talk about the gut-liver axis? Animals (Basel). 2023;13(20):3174. doi: 10.3390/ani13203174. PMID: 37893898. PMC: PMC10603696.
9. Kimmel SE, Waddell LS, Michel KE. Hypomagnesemia and hypocalcemia associated with protein-losing enteropathy in Yorkshire terriers: five cases (1992-1998). J Am Vet Med Assoc. 2000;217(5):703-706. PMID: 10976303.
10. Rudinsky AJ, Howard JP, Bishop MA, Sherding RG, Parker VJ, Gilor C. Dietary management of presumptive protein-losing enteropathy in Yorkshire terriers. J Small Anim Pract. 2017;58(2):103-108. doi: 10.1111/jsap.12625. PMID: 28160309.

---

Editorial Information

Field	Detail
Published	March 2026
Last Updated	March 2026 (original publication)
Reviewed by	Veterinary Advisory Board
Next Review	March 2027
Author	Glendon Lloyd, Dip. Canine Nutrition (Dist.), Dip. Dog Nutrigenomics (Dist.), Founder, Bonza
Disclaimer	This article is for informational purposes only and does not constitute veterinary advice. Always consult a qualified veterinarian before making changes to your dog’s diet or supplement regimen.